Take Part in the Third Era of Medicine

 
  • First to market: NextGen sequencing based mitochondrial diseases diagnostic tests
  • Good connections with clinicians and scientists in Mi IDEA community
  • Extensive proprietary knowledge base of Mi IDEA diseases and associated genome variations
  • IP in proprietary bioinformatics pipeline and unparalleled expert interpretation. Patentable.
  • Most comprehensive testing for each of the 4 Mi IDEA diseases
 

Future:  additional diseases, globalization and mass-consumer food product

Why Invest in MEDomics?

  1. Leader in a rapidly-growing huge market
  2. Unique methods & IP with durable competitive advantages
  3. Field-proven products and services
  4. Led by seasoned pioneers in genostics/pMED